About Us
Translating Genomes | Personalizing Medicine
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company’s proprietary rAAV gene-editing technology, GENESIS, is industry-leading. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has applied GENESIS to create over 400 X-MAN cell lines, the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modelling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.
Founded in 2007, Horizon has become one of the fastest growing biotechnology companies in Europe and now occupies a 20,000 sq. ft. of state-of-art research facility in Cambridge, UK. The company has grown its top-line revenue by greater than 100% every year since foundation, growth that is built upon a customer base that includes 100 academic, biotechnology, diagnostic and pharmaceutical companies. The Company is rapidly leveraging a strong intellectual property, technology and customer base to develop new equity assets (shares, milestones, product royalties) aimed at driving a non-organic growth in its share price. Horizon scientific founders and advisors have been at the forefront of the first test cases for personalized medicine in the field of colorectal cancer and are leading the COLTHERES clinical consortium defining the road-map for the development and diagnosis on new therapeutic regimens for cancer patients.
GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.
Latest News
30.04.12 Horizon Discovery and H3 Biomedicine collaborate to identify and validate novel cancer targets
